http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 10 Sep 2026 07:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Resverlogix+Announces+Publication+of+Scientific+Journal+Articles+Relating+to+Apabetalone%27s+Prevention+of+Heart+Failure/27045079.html <p>Calgary, Alberta--(Newsfile Corp. - September 10, 2026) - Resverlogix Corp.&#160;(TSX: RVX)&#160;("Resverlogix" or the "Company") today announces the publication of two new scientific journal articles on mechanisms relating to heart failure prevention by the Company's lead clinical candidate, apabetalone.</p><p>"One of the most striking findings from BETonMACE was the reduction in heart failure hospitalizations among apabetalone-treated patients," said Dr. Ewelina Kulikowski, PhD, Chief Scientific Officer at Resverlogix. "These publications provide new insights into the biology that may underlie this benefit, suggesting that apabetalone reduces metabolic dysfunction and the formation of damaging scar tissue. Together, these findings strengthen our understanding of apabetalone's potential http://www.streetinsider.com/Press+Releases/Resverlogix+Announces+Publication+of+Scientific+Journal+Articles+Relating+to+Apabetalone%27s+Prevention+of+Heart+Failure/27045079.html Thu, 10 Sep 2026 07:15:00 -0400 RVX http://www.streetinsider.com/Newsfile/Resverlogix+Announces+Publication+of+Scientific+Journal+Articles+Relating+to+Apabetalone%27s+Prevention+of+Heart+Failure/27045079.html <p>Calgary, Alberta--(Newsfile Corp. - September 10, 2026) - Resverlogix Corp.&#160;(TSX: RVX)&#160;("Resverlogix" or the "Company") today announces the publication of two new scientific journal articles on mechanisms relating to heart failure prevention by the Company's lead clinical candidate, apabetalone.</p><p>"One of the most striking findings from BETonMACE was the reduction in heart failure hospitalizations among apabetalone-treated patients," said Dr. Ewelina Kulikowski, PhD, Chief Scientific Officer at Resverlogix. "These publications provide new insights into the biology that may underlie this benefit, suggesting that apabetalone reduces metabolic dysfunction and the formation of damaging scar tissue. Together, these findings strengthen our understanding of apabetalone's potential http://www.streetinsider.com/Newsfile/Resverlogix+Announces+Publication+of+Scientific+Journal+Articles+Relating+to+Apabetalone%27s+Prevention+of+Heart+Failure/27045079.html Thu, 10 Sep 2026 07:15:00 -0400 RVX